<DOC>
	<DOCNO>NCT02475057</DOCNO>
	<brief_summary>The purpose study test whether Degarelix associate less endothelial dysfunction ( intermediate development cardiac disease ) cardiovascular biomarkers compare LHRH agonist .</brief_summary>
	<brief_title>Endothelial Function Prostate Cancer Patients Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists</brief_title>
	<detailed_description>This national multicenter randomize open-label superiority study use Degarelix compare LHRH agonist among men advance prostate cancer pre-existing cardiovascular disease . Patients stratify base baseline endothelial function presence prostate cancer metastasis . Study population : Subjects pre-existing cardiovascular disease locally advance metastatic prostate cancer schedule start Androgen Deprivation Therapy ( ADT ) . Patients already ADT exclude . subject receive either two initial load dos 120mg Degarelix 1 month follow 80mg monthly eleven additional month LHRH agonist discretion treat Urologist/Oncologist 1 year . Follow-up visit occur every 3 month . A blood sample Prostate-specific antigen ( PSA ) , cardiac biomarkers rectal examination perform visit . At baseline 6 12 month EndoPAT2000 measurement take .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<criteria>Male patient locally advance metastatic prostate cancer highrisk prostate cancer . Scheduled start ADT period least one year . Subject history one following : 1 . Myocardial infarction 2 . Ischaemic Haemorrhagic cerebrovascular condition 3 . Arterial embolic thrombotic event , 4 . Ischaemic heart disease 5 . Prior coronary artery iliofemoral artery revascularization ( percutaneous surgical procedure ) 6 . Peripheral vascular disease ( e.g . significant stenosis ( ABPI &lt; 0.9 ) , claudication , prior vascular surgery/intervention ) Life expectancy 12 month . WHO performance status 02 Subject able agree sign consent form . Prior use ADT . However , prior use antiandrogens Casodex , Chimax , Drogenil , Cyprostat allow . Prior use dutasteride/finasteride past 6 month Known allergic reaction Degarelix . Any psychological , familial , sociological geographical situation potentially hamper compliance study protocol followup schedule .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Degarelix</keyword>
</DOC>